FTC Targets Amgen Bundling And Rebates In Suit To Block Horizon Acquisition

Complaint marks first time agency has raised novel theories of competitive harm in pharma merger and is rare instance in which it has filed a complaint without a consent decree. Last time FTC has gone to court to block a pharma merger was in 2008.

FTC building
FTC files complaint to block Amgen's acquisiton of Horizon Therapeutics • Source: Shutterstock

The US Federal Trade Commission signaled its intent to pursue novel theories of anticompetitive harm in reviewing biopharmaceutical transactions two years ago. It finally did so in filing a lawsuit to block Amgen, Inc.’s proposed $27.8bn acquisition of Horizon Therapeutics plc, contending the deal would enable Amgen to use rebates on its existing blockbuster drugs to pressure insurance companies and pharmacy benefit managers into favoring two Horizon products that do not currently have competition.

The redacted complaint, filed on 16 May in the US District Court for the Northern District of Illinois, is...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet